Presentation and pathophysiology of neuro-COVID
Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.
Back to homepage
Tag "Stroke"
Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement
The aim of this study was to assess whether the recommendations and guidelines for thromboprophylaxis in patients with atrial fibrillation (AF) have been adopted in general practice (GP) in the UK. The authors concluded that one in four patients with non-valvular AF, at risk of a stroke, is not being adequately treated with an oral anticoagulant in primary care and suggest that a review of GP practice databases should be considered to identify patients with non-valvular AF, at risk of a disabling or fatal event, and measures taken to initiate anticoagulant therapy.
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
Apixaban, dabigatran and rivaroxaban all have advantages over warfarin for stroke prophylaxis in patients with atrial fibrillation. In this article the author discusses the effect of organ dysfunction on drug disposition, drug–drug interaction potential, and other patient-centered factors to consider when selecting the right antithrombotic therapy for the patient.
